Pyrazolopyridine inhibitors of B-RafV600E. Part 1: The development of selective, orally bioavailable, and efficacious inhibitors

ACS Medicinal Chemistry Letters

Volumn 2, Issue 5, 2011, Pages 342-347

  Wenglowsky, Steve ^a   Ren, Li ^a   Ahrendt, Kateri A ^a   Laird, Ellen R ^a   Aliagas, Ignacio ^b   Alicke, Bruno ^b   Buckmelter, Alex J ^a   Choo, Edna F ^b   Dinkel, Victoria ^a   Feng, Bainian ^b   Gloor, Susan L ^a   Gould, Stephen E ^b   Gross, Stefan ^a   Gunzner Toste, Janet ^b   Hansen, Joshua D ^a   Hatzivassiliou, Georgia ^b   Liu, Bonnie ^b   Malesky, Kim ^b   Mathieu, Simon ^b   Newhouse, Brad ^a   Raddatz, Nicholas J ^a   Ran, Yingqing ^b   Rana, Sumeet ^a   Randolph, Nikole ^a   Risom, Tyler ^a   Rudolph, Joachim ^b   Savage, Scott ^b   Selby, Leann T ^a   Shrag, Michael ^a   Song, Kyung ^b   Sturgis, Hillary L ^a   Voegtli, Walter C ^a   Wen, Zhaoyang ^b   Willis, Brandon S ^a   Woessner, Richard D ^a   Wu, Wen I ^a   Young, Wendy B ^b   Grina, Jonas ^a   more..

^a ARRAY BIOPHARMA INC   (United States)

^b GENENTECH INC   (United States)

Author keywords

amorphous spray dried dispersion; B RafV600E; MAPK pathway; pyrazolopyridine; targeted therapy

Indexed keywords

3 METHOXY PYRAZOLOPYRIDINE; B RAF KINASE; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHOTRANSFERASE INHIBITOR; PYRAZOLOPYRIDINE AMIDE; PYRROLOPYRIDINE AMIDE; UNCLASSIFIED DRUG;

AREA UNDER THE CURVE; ARTICLE; BODY WEIGHT; CANCER CELL CULTURE; CANCER INHIBITION; CELL ACTIVITY; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; DRUG SELECTIVITY; DRUG TARGETING; ENZYME ACTIVITY; GENE MUTATION; IN VIVO STUDY; MOUSE; NONHUMAN; PLASMA PROTEIN BINDING; PRIORITY JOURNAL; XENOGRAFT;

EID: 79956064146     PISSN: None     EISSN: 19485875     Source Type: Journal    
DOI: 10.1021/ml200025q     Document Type: Article

References (34)

1. Peyssonnaux, C.; Eychene, A. The Raf/MEK/ERK pathway: New concepts of activation Biol. Cell. 2001, 93, 53-62 (Pubitemid 33040860)
2. Davies, H.; Bignell, G. R.; Cox, C.; Stephens, P.; Edkins, S.; Clegg, S.; Teague, J.; Woffendin, H.; Garnett, M. J.; Bottomley, W.; Davis, N.; Dicks, E.; Ewing, R.; Floyd, Y.; Gray, K.; Hall, S.; Hawes, R.; Hughes, J.; Kosmidou, V.; Menzies, A.; Mould, C.; Parker, A.; Stevens, C.; Watt, S.; Hooper, S.; Wilson, R.; Jayatilake, H.; Gusterson, B. A.; Cooper, C.; Shipley, J.; Hargrave, D.; Pritchard-Jones, K.; Maitland, N.; Chenevix-Trench, G.; Riggins, G. J.; Bigner, D. D.; Palmieri, G.; Cossu, A.; Flanagan, A.; Nicholson, A.; Ho, J. W. C.; Leung, S. Y.; Yuen, S. T.; Weber, B. L.; Seigler, H. F.; Darrow, T. L.; Paterson, H.; Marais, R.; Marshall, C. J.; Wooster, R.; Stratton, M. R.; Futreal, P. A. Mutations of the BRAF gene in human cancer Nature 2002, 417, 949-954 (Pubitemid 34716871)
3. Pollock., P. M.; Harper, U. L.; Hansen, K. S.; Yudt, L. M.; Stark, M.; Robbins, C. M.; Moses, T. Y.; Hostetter, G.; Wagner, U.; Kakereka, J.; Salem, G.; Pohida, T.; Heenean, P.; Duray, P.; Kallioniemi, O.; Hayward, N. K.; Trent, J. M.; Meltzer, P. S. High frequency of B-Raf mutations in nevi Nat. Genet. 2003, 33, 19-20 (Pubitemid 36068675)
4. Gorden, A.; Osman, I.; Gai, W.; He, D.; Huang, W.; Davidson, A.; Houghton, A. N.; Busam, K.; Polsky, D. Analysis of B-Raf and N-Ras mutations in metastatic melanoma tissues Cancer Res. 2003, 63, 3955-3957 (Pubitemid 36917911)
5. Kuman, R.; Angelini, S.; Czene, K.; Sauroja, I.; Hahka-Kemppinen, M.; Pyrhonen, S.; Hemminki, K. B-Raf mutations in metastatic melanoma: A possible association with clinical outcome Clin. Cancer Res. 2003, 9, 3362-3368 (Pubitemid 37082731)
6. Riesco-Eizaguirre, G.; Santisteban, P. New insights in thyroid follicular cell biology and its impact in thyroid cancer therapy Endocr.-Relat. Cancer 2007, 14, 957-977 (Pubitemid 351252429)
7. Li, Y.; Nakamura, M.; Kakudo, K. Targeting of the BRAF gene in papillary thyroid carcinoma (Review) Oncol. Rep. 2009, 22, 671-681
8. Tannapfel, A.; Sommerer, F.; Benicke, M.; Katalinic, A.; Uhlmann, D.; Witzigmann, H.; Hauss, J.; Wittekind, C. Mutations of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinoma Gut 2003, 52, 706-712 (Pubitemid 36528874)
9. Wan, P. T.; Garnett, M. J.; Roe, S. M.; Lee, S.; Niculescu-Duvaz, D.; Good, V. M.; Jones, C. M.; Marshall, C. J.; Springer, C. J.; Barford, D.; Marais, R. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF Cell 2004, 116, 855-867 (Pubitemid 38410730)
10. Samowitz, W. S.; Sweeney, C.; Herrick, J.; Albertsen, H.; Levin, T. R.; Murtaugh, M. A.; Wolff, R. K.; Slattery, M. L. Poor survival associated with the BRAF V600E mutation in microsatellite-stable colon cancers Cancer Res. 2005, 65, 6063-6069
11. Riesco-Eizaguirre, G.; Gutierrez-Martinez, P.; Garcia-Cabezas, M. A.; Mistal, M.; Santisteban, P. The oncogene BRAF V600E is associated with a high risk of recurrence and less differentiated papillary thyroid carcinoma due to the impairment of Na+/I-targeting to the membrane Endocr.-Relat. Cancer 2006, 13, 257-269
12. Houben, R.; Becker, J. C.; Kappel, A.; Terheyden, P.; Bröcker, E. B.; Goetz, R.; Rapp, U. R. Constitutive activation of the Ras-Raf signaling pathway in metastatic melanoma is associated with poor prognosis J. Carcinog. 2004, 3, 6-18
13. Sawyers, C. Targeted cancer therapy Nature 2004, 432, 294-297 (Pubitemid 39551656)
14. Johnson, L. N. Protein kinase inhibitors: Contributions from structure to clinical compounds Q. Rev. Biophys. 2009, 42, 1-40
15. ClinicalTrials.gov web site. http://www.clinicaltrials.gov (accessed Feb 22, 2011). A study to evaluate RAF265, an oral drug administered to subjects with locally advanced or metastatic melanoma.
16. Schwartz, G. L.; Robertson, S.; Shen, A.; Wang, E.; Pace, L.; Dials, H.; Mendelson, D.; Shannon, P.; Gordon, M. A phase I study of XL281, a selective oral RAF kinase inhibitor, in patients (Pts) with advanced solid tumors J. Clin. Oncol. 2009, 27, 15s Abstr. 3513
17. Kefford, R.; Arkenau, H.; Brown, M. P.; Millward, M.; Infante, J. R.; Long, G. V.; Ouellet, D.; Curtis, M.; Lebowitz, P. F.; Falchook, G. S. Phase I/II study of GSK2118436, a selective inhibitor of oncogenic mutant BRAF kinase, in patients with metastatic melanoma and other solid tumors J. Clin Oncol. 2010, 28, 15s Abstr. 8503
18. Flaherty, K. T.; Puzanov, I.; Kim, K. B.; Ribas, A.; McArthur, G. A.; Sosman, J. A.; O'Dwyer, P. J.; Lee, R. J.; Grippo, J. F.; Nolop, K.; Chapman, P. B. Inhibition of mutated, activated BRAF in metastatic melanoma N. Engl. J. Med. 2010, 363, 809-819
19. King, A. J.; Patrick, D. R.; Batorsky, R. S.; Ho, M. L; Do, H. T.; Zhang, S. Y.; Kumar, R.; Rusnak, D. W.; Takle, A. K.; Wilson, D. M.; Hugger, E.; Wang, L.; Karreth, F.; Lougheed, J. C.; Lee, J.; Chau, D.; Stout, T. J.; May, E. W.; Rominger, C.; M.; Schaber, M.; D.; Luo, L.; Lakdawala, A. S.; Adams, J. L.; Contractor, R. G.; Smalley, K. S. M.; Herlyn, M.; Morrissey, M. M.; Tuveson, D. A.; Huang, P. S. Demonstration of a Genetic Therapeutic Index for Tumors Expressing Oncogenic BRAF by the Kinase Cancer Res. 2006, 66, 11100-11105 (Pubitemid 46009933)
20. V600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression Cancer Res. 2009, 69, 3042-3051
21. Tang, J.; Hamajima, T.; Nakano, M.; Sato, H.; Dickerson, S. H.; Lackey, K. E. Knowledge-based design of 7-azaindoles as selective B-Raf inhibitors Bioorg. Med. Chem. Lett. 2008, 18, 4610-4614
22. Smith, A. L.; DeMorin, F. F.; Paras, M. A.; Huang, Q.; Petkus, J. K.; Doherty, E. M.; Nixey, T.; Kim, J. L.; Whittington, D. A.; Epstein, L. F.; Lee, M. R.; Rose, M. J.; Babij, C.; Fernando, M.; Hess, K.; Le, Q.; Beltran, P.; Carnahan, J. Selective inhibitors of the mutant B-Raf pathway: Discovery of a potent and orally bioavailable aminoisoquinoline J. Med. Chem. 2009, 52, 6289-6292
23. Bollag, G.; Hirth, P.; Tsai, J.; Zhang, J.; Ibrahim, P. N.; Cho, H.; Spevak, W.; Zhang, C.; Zhang, Y.; Habets, G.; Burton, E. A.; Wong, B.; Tsang, G.; West., B. L.; Powell, B.; Shellooe, R.; Marimuthu, A.; Nguyen, H.; Zhang, K. Y. J.; Artis, D. R.; Schlessinger, J.; Su, F.; Higgins, B.; Iyer, R.; D'Andrea, K.; Koehler, A.; Stumm, M.; Lin., P. S.; Lee, R. J.; Grippo, J.; Puzanov, I.; Kim, K. B.; Ribas, A.; McArthur, G. A.; Sosman, J. A.; Chapman, P. B.; Flaherty, K. T.; Xu, X.; Nathanson, K. L.; Nolop, K. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma Nature 2010, 467, 596-599
24. Via a substituted benzyl ether, lapatinib also traps a shifted αC-helix in EGFR kinase, which similarly leads to high kinase selectivity: Wood, E. R.; Truesdale, A. T.; McDonald, O. B.; Yuan, D.; Hassell, A.; Dickerson, S. H.; Ellis, B.; Pennisi, C.; Horne, E.; Lackey, K.; Alligood, K. J.; Rusnak, D. W.; Gilmer, T. M.; Shewchuk, L. A unique structure for epidermal growth factor receptor bound to GW572016 (lapatinib): Relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells Cancer Res. 2004, 64, 6652-6659 (Pubitemid 39297926)
25. Ahrendt, K. A.; Buckmelter, A. J.; De Meese, J.; Grina, J.; Hansen, J. D.; Laird, E. R.; Lunghofer, P.; Moreno, D.; Newhouse, B.; Ren, L.; Seo, J.; Tian, H.; Wenglowsky, S. M.; Feng, B.; Gunzner, J.; Malesky, K.; Mathieu, S.; Rudolph, J.; Wen, Z.; Young, W. B. N-Pyrazolo[3,4-b]pyridinyl benzamide derivatives as Raf inhibitors and their preparation, pharmaceutical compositions and use in the treatment of diseases. WO 2009/111279.
26. Wallace, E. M.; Lyssikatos, J.; Blake, J. F.; Seo, J.; Yang, H. W.; Yeh, T. C.; Perrier, M.; Jarski, H.; Marsh, V.; Poch, G.; Livingston, M. G.; Otten, J.; Hingorani, G.; Woessner, R.; Lee, P.; Winkler, J.; Koch, K. Potent and selective mitogen-activated protein kinase kinase (MEK) 1,2 inhibitors. 1. 4-(4-bromo2-2fluorophenylamino)-1-methylpyridin-2(1 H)-ones J. Med. Chem. 2006, 49, 441-444 (Pubitemid 43157473)
27. Lynch, B. M.; Khan, M. A.; Teo, H. C.; Pedrotti, F. Pyrazolo[3,4-b] pyridines: Syntheses, reactions, and nuclear magnetic resonance spectra Can. J. Chem. 1988, 66, 420-428
28. Blake, J.; Gunawardana, I. W.; Le Huerou, Y.; Mohr, P. J.; Wallace, E. M.; Wang, B. Pyrazolopyridine derivatives and their pharmaceutical compositions as CHK1 and CHK2 kinase inhibitors for the treatment of various diseases and preparation thereof. WO 2009/089359.
29. Friesen, D. T.; Shanker, R.; Crew, M.; Smithey, D. T.; Curatolo, W. J.; Nightingale, J. A. S. Hydroxypropyl methylcellulose acetate succinate-based spray-dried dispersions: An overview Mol. Pharmaceutics 2008, 5, 1003-1019
30. Details and discussion regarding the relationship between pERK inhibition and tumor response will be reported: Choo, E. F.; Afflerbaugh, L.; Alicke, B.; Boggs, J.; Dinkel, D.; Gould, S.; Grina, J.; West, K.; Menghrajani, K.; Ran, Y.; Rudolph, J.; Wenglowsky, S. Preclinical Assessment of Novel B-RAF Inhibitors: Integrating Pharmacokinetic-Pharmacodynamic Modeling in the Drug Discovery Process. Xenobiotica, manuscript in preparation.
31. Hatzivassiliou, G.; Song, K.; Yen, I.; Brandhuber, B. J.; Anderson, D. J.; Alvarado, R.; Ludlam, M. C.; Stokoe, D.; Gloor, S. L.; Vigers, G.; Morales, T.; Aliagas, I.; Liu, B.; Siberis, S.; Hoeflich, K. P.; Jaiswal, B. S.; Seshagiri, S.; Koeppen, H.; Belvin, M.; Friedman, L. S.; Malek, S. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth Nature 2010, 464, 431-435
32. Heidhorn, S. J.; Milagre, C.; Whittaker, S.; Nourry, A.; Niculescu-Duvas, I.; Dhomen, N.; Hussain, J.; Reis-Filho, J.; Springer, C. J.; Pritchard, C.; Marais, R. Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF Cell 2010, 140, 209-221
33. Poulikakos, P.; Zhang, C.; Bollag, G.; Shokat, K. M.; Rosen, N. RAF inhibitors transactivate RAF dimers and ERK signaling in cells with wild-type BRAF Nature 2010, 464, 427-430
34. Carnahan, J.; Beltran, P. J.; Babij, C.; Le, Q.; Rose, M. J.; Vonderfecht, S.; Kim, J. L.; Smith, A. L.; Nagapudi, K.; Broome, M. A.; Fernando, M.; Kha, H.; Belmontes, B.; Radinsky, R.; Kendall, R.; Burgess, T. L. Selective and potent Raf inhibitors paradoxically stimulate normal cell proliferation and tumor growth Mol. Cancer Ther. 2010, 9, 2399-2410